42 Percent Drop in Melanoma Risk Marks Major Cancer Breakthrough

Cancer treatments have long been a one-size-fits-all affair, but a new personalized approach is changing that. This week, Merck and Moderna announced that their tailored mRNA vaccine for melanoma reduced the risk of death or recurrence by 42 percent compared to standard care alone.

The data comes from a late-stage trial involving 1,137 patients with stage IIB through IV melanoma. All participants had the cancer surgically removed before joining the study. Researchers randomized the patients in a two-to-one ratio. Those in the larger group received the personalized mRNA vaccine alongside Merck’s standard monoclonal antibody treatment, Keytruda. The smaller group received only the Keytruda therapy.

The results represent a significant step forward in how doctors might treat this deadliest form of skin cancer. The companies are already working with regulatory authorities to seek approval for the vaccine. Beyond this specific drug, the success suggests that individualized medicines targeting a patient’s unique tumor profile could become a new standard in oncology.

Moderna CEO Stéphane Bancel emphasized the potential of the technology in a statement. He noted that the company has believed since the start that mRNA could create treatments uniquely matched to each patient’s tumor. He described the results as a defining moment for that vision. Bancel added that the findings reinforce his conviction that mRNA has the potential to fundamentally change cancer treatment.

The announcement was made on Thursday, slightly ahead of schedule. In August, the partners confirmed the vaccine had succeeded in the trial but withheld details until they could present them at a scientific conference. The European Society of Medical Oncology meeting is currently underway in Madrid, Spain. The data was set for a Saturday presentation. However, after an oncology news site reported the results early and broke the embargo, the companies released the top-line numbers immediately. The full dataset has been accepted for publication in the New England Journal of Medicine.

Regulatory reviews will proceed as the partners move toward a formal application. For now, the focus remains on the immediate impact of the 42 percent risk reduction. The study provides strong evidence that combining standard immunotherapy with personalized mRNA vaccines can offer superior protection against melanoma returning.